You are here:

  1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Diabetes and other endocrinal, nutritional and metabolic conditions
  5. Diet, nutrition and obesity

Semaglutide for managing overweight and obesity

  • Technology appraisal guidance
  • Reference number: TA875
  • Published:  08 March 2023
  • Last updated:  04 September 2023
  • Guidance
  • Tools and resources
  • Information for the public
  • Evidence
  • History

On this page

  1. Summary versions
  2. Resource impact
  3. Case studies
  4. Guidance into practice

Tools and resources

Tools and resources to help you put the guidance into practice.

Summary versions

  • Summary of NICE guidance for GLP-1 receptor agonists and tirzepatide in adults (PDF 230 KB)

    Published:
    11 May 2026

Resource impact

  • Resource impact report (PDF 210 KB)

    Published:
    22 August 2025
  • Resource impact template (Excel 2.38 MB)

    Published:
    01 September 2025
  • Resource impact template and summary report

  • Resource impact summary report

Case studies

  • Injectable anti-obesity medications in specialist weight management services: supporting people with complex needs

Guidance into practice

  • About the Into practice guide

  • Practical steps to improving the quality of care and services using NICE guidance

Back to top